⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490276 | 0.88 | — | — | |
| SCHEMBL19448472 | 0.77 | — | — | |
| SCHEMBL2010687 | 0.76 | — | — | |
| SCHEMBL27373666 | 0.74 | — | — | |
| SCHEMBL38657821 | 0.73 | GRM5 (0.33) | — | |
| SCHEMBL38658449 | 0.73 | GRM5 (0.33) | — | |
| SCHEMBL286213 | 0.72 | HSD17B10 (0.30) | — | |
| SCHEMBL2830673 | 0.71 | MEN1 (0.35) | — | |
| SCHEMBL19448446 | 0.71 | — | — | |
| SCHEMBL22319209 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20250042889-A1 | 3CLPRO PROTEASE INHIBITOR | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| WO-2024183629-A1 | USE OF 3CLPRO INHIBITOR IN PREPARATION OF DRUG FOR TREATING DISEASES CAUSED BY FELINE CORONAVIRUS | 齐鲁动物保健品有限公司 | 2024-09-12 | — | — | WO | disclosed |
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| CN-118076593-A | 3CLpro protease inhibitors | 上海齐鲁制药研究中心有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4194450-A1 | CDK9 INHIBITOR AND USE THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2023-06-14 | — | — | EP | disclosed |
| CN-111164084-B | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023036140-A1 | 3CLPRO PROTEASE INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2023-03-16 | — | — | WO | disclosed |
| CN-108601788-B | EIF 4A-inhibiting compounds and methods relating thereto | 效应治疗股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-11066419-B2 | 1H-pyrrole-2,5-dione compounds and methods of using same | Frequency Therapeutics, Inc. (US) | 2021-07-20 | — | — | US | disclosed |
| CN-109053742-B | Novel tricyclic compounds | ABBVIE 公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-111164084-A | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2020-05-15 | — | — | CN | disclosed |
| WO-2018098128-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-05-31 | — | — | WO | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |